Six-Month Study of Dapagliflozin Effects on Patients with End-Stage Kidney Disease Undergoing Chronic Peritoneal Dialysis

What this Trial Is About

Researchers are evaluating the effects of a six-month treatment with the selective SGLT2 inhibitor, dapagliflozin, in patients with end-stage kidney disease who are on chronic peritoneal dialysis. This study includes both diabetic and non-diabetic patients and aims to understand how dapagliflozin impacts dialysis adequacy, ultrafiltration volume, and urine output. The trial is an open-label, single-arm interventional study conducted at Nizwa Hospital. Participants will receive dapagliflozin 10 mg once daily for six months. The study will monitor clinical and laboratory parameters at the start, three months, and six months after beginning treatment. The focus is on measuring changes in ultrafiltration volume, dialysis adequacy as measured by KtV, and 24-hour urine volume. The study includes thirty patients undergoing peritoneal dialysis. Throughout the study, participants will have assessments at baseline, three months, and six months to evaluate blood glucose levels, ultrafiltration volume, and residual kidney function. Researchers will track laboratory and clinical data, including inflammatory markers and dialysis performance. Safety and treatment effects will be monitored, with the total participation lasting six months.

Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.